Sökning: WFRF:(Hauptmann Michael) >
Adjuvant capecitabi...
Adjuvant capecitabine-containing chemotherapy benefit and homologous recombination deficiency in early-stage triple-negative breast cancer patients
-
- de Boo, Leonora W. (författare)
- Netherlands Canc Inst, Div Mol Pathol, Amsterdam, Netherlands
-
- Jozwiak, Katarzyna (författare)
- Brandenburg Med Sch Theodor Fontane, Inst Biostat & Registry Res, Neuruppin, Germany.;Netherlands Canc Inst, Dept Epidemiol & Biostat, Amsterdam, Netherlands
-
- Joensuu, Heikki (författare)
- Helsinki Univ Hosp, Dept Oncol, Helsinki, Finland.;Univ Helsinki, Helsinki, Finland
-
visa fler...
-
- Lindman, Henrik (författare)
- Uppsala universitet,Experimentell och klinisk onkologi
-
- Lauttia, Susanna (författare)
- Univ Helsinki, Lab Mol Oncol, Biomed Helsinki, Helsinki, Finland
-
- Opdam, Mark (författare)
- Netherlands Canc Inst, Div Mol Pathol, Amsterdam, Netherlands
-
- van Steenis, Charlaine (författare)
- Netherlands Canc Inst, Genom Core Facil, Amsterdam, Netherlands
-
- Brugman, Wim (författare)
- Netherlands Canc Inst, Genom Core Facil, Amsterdam, Netherlands
-
- Kluin, Roelof J. C. (författare)
- Netherlands Canc Inst, Genom Core Facil, Amsterdam, Netherlands
-
- Schouten, Philip C. (författare)
- Netherlands Canc Inst, Div Mol Pathol, Amsterdam, Netherlands
-
- Kok, Marleen (författare)
- Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands.;Netherlands Canc Inst, Div Tumor Biol & Immunol, Amsterdam, Netherlands
-
- Nederlof, Petra M. (författare)
- Antoni van Leeuwenhoek Hosp, Dept Pathol, Netherlands Canc Inst, Amsterdam, Netherlands
-
- Hauptmann, Michael (författare)
- Brandenburg Med Sch Theodor Fontane, Inst Biostat & Registry Res, Neuruppin, Germany.;Netherlands Canc Inst, Dept Epidemiol & Biostat, Amsterdam, Netherlands
-
- Linn, Sabine C. (författare)
- Netherlands Canc Inst, Div Mol Pathol, Amsterdam, Netherlands.;Netherlands Canc Inst, Dept Med Oncol, Amsterdam, Netherlands.;Univ Med Ctr, Dept Pathol, Utrecht, Netherlands
-
visa färre...
-
Netherlands Canc Inst, Div Mol Pathol, Amsterdam, Netherlands Brandenburg Med Sch Theodor Fontane, Inst Biostat & Registry Res, Neuruppin, Germany;Netherlands Canc Inst, Dept Epidemiol & Biostat, Amsterdam, Netherlands (creator_code:org_t)
- 2022-02-05
- 2022
- Engelska.
-
Ingår i: British Journal of Cancer. - : Springer Nature. - 0007-0920 .- 1532-1827. ; 126:10, s. 1401-1409
- Relaterad länk:
-
https://doi.org/10.1...
-
visa fler...
-
https://uu.diva-port... (primary) (Raw object)
-
https://www.nature.c...
-
https://urn.kb.se/re...
-
https://doi.org/10.1...
-
visa färre...
Abstract
Ämnesord
Stäng
- Background The addition of adjuvant capecitabine to standard chemotherapy of early-stage triple-negative breast cancer (TNBC) patients has improved survival in a few randomised trials and in meta-analyses. However, many patients did not benefit. We evaluated the BRCA1-like DNA copy number signature, indicative of homologous recombination deficiency, as a predictive biomarker for capecitabine benefit in the TNBC subgroup of the FinXX trial.Methods Early-stage TNBC patients were randomised between adjuvant capecitabine-containing (TX + CEX: capecitabine-docetaxel, followed by cyclophosphamide-epirubicin-capecitabine) and conventional chemotherapy (T + CEF: docetaxel, followed by cyclophosphamide-epirubicin-fluorouracil). Tumour BRCA1-like status was determined on low-coverage, whole genome next-generation sequencing data using an established DNA comparative genomic hybridisation algorithm.Results For 129/202 (63.9%) patients the BRCA1-like status could be determined, mostly due to lack of tissue. During a median follow-up of 10.7 years, 35 recurrences and 32 deaths occurred. Addition of capecitabine appears to improve recurrence-free survival more among 61 (47.3%) patients with non-BRCA1-like tumours (HR 0.23, 95% CI 0.08-0.70) compared to 68 (52.7%) patients with BRCA1-like tumours (HR 0.66, 95% CI 0.24-1.81) (P-interaction = 0.17).Conclusion Based on our data, patients with non-BRCA1-like TNBC appear to benefit from the addition of capecitabine to adjuvant chemotherapy. Patients with BRCA1-like TNBC may also benefit. Additional research is needed to define the subgroup within BRCA1-like TNBC patients who may not benefit from adjuvant capecitabine.
Ämnesord
- MEDICIN OCH HÄLSOVETENSKAP -- Klinisk medicin -- Cancer och onkologi (hsv//swe)
- MEDICAL AND HEALTH SCIENCES -- Clinical Medicine -- Cancer and Oncology (hsv//eng)
Publikations- och innehållstyp
- ref (ämneskategori)
- art (ämneskategori)
Hitta via bibliotek
Till lärosätets databas
- Av författaren/redakt...
-
de Boo, Leonora ...
-
Jozwiak, Katarzy ...
-
Joensuu, Heikki
-
Lindman, Henrik
-
Lauttia, Susanna
-
Opdam, Mark
-
visa fler...
-
van Steenis, Cha ...
-
Brugman, Wim
-
Kluin, Roelof J. ...
-
Schouten, Philip ...
-
Kok, Marleen
-
Nederlof, Petra ...
-
Hauptmann, Micha ...
-
Linn, Sabine C.
-
visa färre...
- Om ämnet
-
- MEDICIN OCH HÄLSOVETENSKAP
-
MEDICIN OCH HÄLS ...
-
och Klinisk medicin
-
och Cancer och onkol ...
- Artiklar i publikationen
-
British Journal ...
- Av lärosätet
-
Uppsala universitet